BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 06, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

IMO-2055: Phase Ib started

Idera said Merck began a dose-escalation Phase Ib trial to evaluate IMO-2055 in combination with cisplatin, fluorouracil and Erbitux cetuximab in first-line patients. The start triggered a milestone payment of $3.8 million to Idera from Merck,...

Read the full 170 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >